Novo Nordisk A/S $NVO Shares Sold by Inspire Trust Co. N.A.

Inspire Trust Co. N.A. cut its holdings in Novo Nordisk A/S (NYSE:NVO) by 42.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,000 shares of the company’s stock after selling 15,000 shares during the quarter. Inspire Trust Co. N.A.’s holdings in Novo Nordisk A/S were worth $1,018,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Guerra Advisors Inc acquired a new position in Novo Nordisk A/S in the third quarter valued at $25,000. Godfrey Financial Associates Inc. acquired a new position in Novo Nordisk A/S in the fourth quarter valued at $25,000. WealthCollab LLC increased its stake in Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after purchasing an additional 260 shares during the period. American National Bank & Trust acquired a new position in Novo Nordisk A/S in the fourth quarter valued at $28,000. Finally, Maseco LLP acquired a new position in Novo Nordisk A/S in the fourth quarter valued at $29,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Up 2.2%

Shares of Novo Nordisk A/S stock opened at $45.51 on Friday. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The company’s 50-day simple moving average is $40.81 and its 200-day simple moving average is $46.38. The firm has a market cap of $203.19 billion, a price-to-earnings ratio of 10.68, a price-to-earnings-growth ratio of 3.97 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion for the quarter. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.46 earnings per share for the current year.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk highlighted new cardiometabolic pipeline data, including Phase 3 results for CagriSema, and said it will present 40 abstracts at the upcoming ADA Scientific Sessions, reinforcing the company’s growth pipeline. Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association’s 2026 Scientific Sessions
• Positive Sentiment: Some commentary argues Novo Nordisk may be undervalued after recent earnings strength and a slightly raised full-year outlook, suggesting the stock could still have room to recover if execution improves. Novo Nordisk (NVO) Among Our Most Undervalued Foreign Stocks to Buy Now
• Neutral Sentiment: At a Deutsche Bank conference, Novo said its oral semaglutide launch patterns are not yet matching the fast uptake seen in injectables, and the broker kept a Hold rating, which points to execution uncertainty rather than a major new setback. Novo Nordisk faces complex GLP-1 landscape as oral launch patterns diverge from injectables
• Negative Sentiment: CVS Caremark’s expanded coverage for Lilly’s Zepbound and weight-loss pill improves patient access for a key rival, potentially pressuring Novo Nordisk’s competitive position in the obesity-drug market. CVS Caremark adds Zepbound and Foundayo to formulary
• Negative Sentiment: Broader reports that CVS is restoring coverage for Lilly’s obesity drugs strengthen the perception that Novo Nordisk faces tougher competition for insurer access and market share. CVS Restores Coverage for Lilly’s Zepbound

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on NVO. Wall Street Zen upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Morgan Stanley upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target on the stock in a research note on Tuesday, March 3rd. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Finally, Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.